FindTrial
Sign In

OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517560-30-00
Enrollment
22
Registered
2024-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar depression

Brief summary

Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) [Time Frame: Day 0, 5, 12, 30, 45, 60].

Interventions

DRUGOSU6162 15 mg

Sponsors

University Of Gothenburg
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) [Time Frame: Day 0, 5, 12, 30, 45, 60].—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026